JP2024529119A - 抗vegfaとvegfc二重特異性抗体およびその使用 - Google Patents

抗vegfaとvegfc二重特異性抗体およびその使用 Download PDF

Info

Publication number
JP2024529119A
JP2024529119A JP2024508417A JP2024508417A JP2024529119A JP 2024529119 A JP2024529119 A JP 2024529119A JP 2024508417 A JP2024508417 A JP 2024508417A JP 2024508417 A JP2024508417 A JP 2024508417A JP 2024529119 A JP2024529119 A JP 2024529119A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antibody
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529119A5 (cg-RX-API-DMAC7.html
Inventor
イーミン リー
スーイー フー
ピンリャン チェン
ショアイシアン チョウ
Original Assignee
イノベント バイオロジクス(スーチョウ)カンパニー,リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノベント バイオロジクス(スーチョウ)カンパニー,リミティド filed Critical イノベント バイオロジクス(スーチョウ)カンパニー,リミティド
Publication of JP2024529119A publication Critical patent/JP2024529119A/ja
Publication of JP2024529119A5 publication Critical patent/JP2024529119A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024508417A 2021-08-13 2022-08-11 抗vegfaとvegfc二重特異性抗体およびその使用 Pending JP2024529119A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110932078 2021-08-13
CN202110932078.7 2021-08-13
PCT/CN2022/111717 WO2023016516A1 (zh) 2021-08-13 2022-08-11 抗vegf a和vegf c双特异性抗体及其用途

Publications (2)

Publication Number Publication Date
JP2024529119A true JP2024529119A (ja) 2024-08-01
JP2024529119A5 JP2024529119A5 (cg-RX-API-DMAC7.html) 2025-08-15

Family

ID=85200580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508417A Pending JP2024529119A (ja) 2021-08-13 2022-08-11 抗vegfaとvegfc二重特異性抗体およびその使用

Country Status (7)

Country Link
US (1) US20250002570A1 (cg-RX-API-DMAC7.html)
EP (1) EP4386004A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024529119A (cg-RX-API-DMAC7.html)
CN (1) CN118043350A (cg-RX-API-DMAC7.html)
AU (1) AU2022327397B2 (cg-RX-API-DMAC7.html)
CA (1) CA3229250A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023016516A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165077A1 (zh) * 2023-02-10 2024-08-15 信达生物制药(苏州)有限公司 一种包含抗vegfa和vegfc双特异性结合蛋白的药物制剂
WO2025250739A1 (en) * 2024-05-31 2025-12-04 Janssen Biotech, Inc. Chimeric antigen receptor with spacer domains derived from human igg

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535819A (ja) * 2005-03-25 2008-09-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Vegfアンタゴニスト製剤
JP2012518400A (ja) * 2009-02-24 2012-08-16 グラクソ グループ リミテッド 多価および/または複数特異的rankl結合性構築物
JP2013513383A (ja) * 2009-12-11 2013-04-22 ジェネンテック, インコーポレイテッド 抗vegf−c抗体及びその使用方法
US20150110787A1 (en) * 2013-10-18 2015-04-23 Samsung Electronics Co., Ltd. Polypeptide specifically binding to vegf-c and use thereof
JP2018516546A (ja) * 2015-04-24 2018-06-28 ジェネンテック, インコーポレイテッド 多特異性抗原結合タンパク質
WO2020077169A1 (en) * 2018-10-12 2020-04-16 Trican Biotechnology Co., Ltd Bi-functional fusion proteins and uses thereof
JP2020516287A (ja) * 2017-04-11 2020-06-11 インヒブルクス インコーポレイテッド 制約されたcd3結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法
WO2020176815A2 (en) * 2019-02-27 2020-09-03 Zhejiang Nanomab Technology Center Co. Ltd. Sequence-based high throughput method generating camelids antibodies to cover broad epitopes with high-resolution
CN112552412A (zh) * 2019-12-05 2021-03-26 屈向东 一种包含TGF-β抑制剂、VEGF抑制剂和抗PDL1抗体的三功能融合蛋白
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CN112961250A (zh) * 2021-03-01 2021-06-15 长春金赛药业有限责任公司 抗体融合蛋白及其应用
JP2021516952A (ja) * 2018-03-27 2021-07-15 イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド 新規な抗体分子、その調製方法及びその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403088B1 (en) * 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
CA2796205A1 (en) * 2010-04-15 2011-10-20 Vegenics Pty Limited Combination treatment with vegf-c antagonists
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
PH12014500220A1 (en) * 2011-07-27 2019-03-22 Glaxo Group Ltd Anti-vegf single variable domains fused to fc domains
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535819A (ja) * 2005-03-25 2008-09-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Vegfアンタゴニスト製剤
JP2012518400A (ja) * 2009-02-24 2012-08-16 グラクソ グループ リミテッド 多価および/または複数特異的rankl結合性構築物
JP2013513383A (ja) * 2009-12-11 2013-04-22 ジェネンテック, インコーポレイテッド 抗vegf−c抗体及びその使用方法
US20150110787A1 (en) * 2013-10-18 2015-04-23 Samsung Electronics Co., Ltd. Polypeptide specifically binding to vegf-c and use thereof
JP2018516546A (ja) * 2015-04-24 2018-06-28 ジェネンテック, インコーポレイテッド 多特異性抗原結合タンパク質
JP2020516287A (ja) * 2017-04-11 2020-06-11 インヒブルクス インコーポレイテッド 制約されたcd3結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法
JP2021516952A (ja) * 2018-03-27 2021-07-15 イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド 新規な抗体分子、その調製方法及びその使用
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2020077169A1 (en) * 2018-10-12 2020-04-16 Trican Biotechnology Co., Ltd Bi-functional fusion proteins and uses thereof
WO2020176815A2 (en) * 2019-02-27 2020-09-03 Zhejiang Nanomab Technology Center Co. Ltd. Sequence-based high throughput method generating camelids antibodies to cover broad epitopes with high-resolution
CN112552412A (zh) * 2019-12-05 2021-03-26 屈向东 一种包含TGF-β抑制剂、VEGF抑制剂和抗PDL1抗体的三功能融合蛋白
CN112961250A (zh) * 2021-03-01 2021-06-15 长春金赛药业有限责任公司 抗体融合蛋白及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MABS, vol. 8, no. 8, JPN6026025578, 2016, pages 1467 - 1476, ISSN: 0005892144 *
PLOS ONE, vol. 5, no. 8, JPN6026025577, 2010, pages 11941, ISSN: 0005892143 *

Also Published As

Publication number Publication date
AU2022327397B2 (en) 2026-06-18
AU2022327397A1 (en) 2024-03-14
WO2023016516A1 (zh) 2023-02-16
US20250002570A1 (en) 2025-01-02
CA3229250A1 (en) 2023-02-16
CN118043350A (zh) 2024-05-14
EP4386004A1 (en) 2024-06-19
EP4386004A4 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
US20220235123A1 (en) Synthetic antibodies against vegf and their uses
JP5823858B2 (ja) 抗vegf抗体
US20240247057A1 (en) Bispecific binding molecule binding to vegf and ang2 and use thereof
KR20210141992A (ko) Vegf 및 ang2에 특이적으로 결합되는 이중특이적 항체
KR20140019375A (ko) 인간 조직 인자 항체 및 이의 용도
KR20240004860A (ko) 디엘엘3에 대한 결합 분자 및 이의 용도
US11008387B2 (en) Antibody inhibiting binding of VEGF to NRP1
JP2024502091A (ja) Pd-1結合分子およびその使用
US20260009804A1 (en) Antibodies that bind to natively folded myocilin
US20250002570A1 (en) Anti-vegf a and vegf c bispecific antibodies and use thereof
WO2024114746A1 (zh) 包含结合VEGF和Ang2的双特异性结合分子的制剂以及其用途
KR20250139273A (ko) 삼중특이적 융합 단백질 및 이의 용도
JP2026506572A (ja) 抗vegfaおよびvegfc二重特異性結合タンパク質を含む医薬製剤
AU2021294703A1 (en) Anti-ANG-2 antibody and use thereof
TW202302641A (zh) 針對IL-13Rα2的抗體及其應用
WO2025113639A1 (zh) 抗gdf15的抗体及其方法和用途
WO2024188179A1 (zh) 一种靶向ctgf的抗体或其抗原结合片段及其应用
JP2024506664A (ja) 抗vegf抗体およびその使用
CN118791607A (zh) 双特异性抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250806

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260623